GAROFALO, MARIANGELA
 Distribuzione geografica
Continente #
NA - Nord America 2.482
AS - Asia 516
EU - Europa 414
SA - Sud America 71
AF - Africa 8
OC - Oceania 2
Totale 3.493
Nazione #
US - Stati Uniti d'America 2.478
SG - Singapore 277
IT - Italia 210
CN - Cina 177
BR - Brasile 71
DE - Germania 38
FR - Francia 28
GB - Regno Unito 28
FI - Finlandia 26
VN - Vietnam 25
RU - Federazione Russa 21
IR - Iran 19
PL - Polonia 17
HK - Hong Kong 12
NL - Olanda 12
AT - Austria 10
IE - Irlanda 6
ES - Italia 5
UA - Ucraina 5
CI - Costa d'Avorio 4
SE - Svezia 3
CA - Canada 2
DZ - Algeria 2
GR - Grecia 2
IN - India 2
KR - Corea 2
NZ - Nuova Zelanda 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EG - Egitto 1
HN - Honduras 1
IQ - Iraq 1
MA - Marocco 1
TH - Thailandia 1
Totale 3.493
Città #
Fairfield 508
Seattle 224
Ashburn 221
Woodbridge 211
Cambridge 177
Houston 170
Singapore 149
Wilmington 134
Chandler 116
Ann Arbor 89
Padova 87
Boardman 76
Santa Clara 75
San Diego 55
Medford 45
Princeton 45
Beijing 33
Des Moines 28
Dong Ket 25
Milan 20
Helsinki 19
Bytom 17
Jinan 14
Hong Kong 12
Nuremberg 12
Shenyang 12
London 11
Roxbury 11
Nanjing 9
São Paulo 9
Dearborn 6
Dublin 6
Hebei 6
Zhengzhou 6
Fossò 5
Guangzhou 5
Haikou 5
Nanchang 5
Shanghai 5
Abidjan 4
Belo Horizonte 4
Changsha 4
Codognè 4
Falls Church 4
Hangzhou 4
Kharkiv 4
Ningbo 4
Rio de Janeiro 4
Strasbourg 4
Vienna 4
Brasília 3
Bresso 3
Hefei 3
Kunming 3
Lappeenranta 3
Lauterbourg 3
Munich 3
Tappahannock 3
Turku 3
Algiers 2
Arzignano 2
Borås 2
Campobasso 2
Chicago 2
Chivasso 2
Germering 2
Kilburn 2
Lanzhou 2
Leopoldina 2
Logroño 2
Montesilvano Marina 2
Norwalk 2
Parma 2
Pohang 2
Portsmouth 2
Redmond 2
Reggio Nell'emilia 2
Rimini 2
Santo André 2
Wuhan 2
Al Jam'iyah 1
Almirante Tamandaré 1
Andradina 1
Arapiraca 1
Arre 1
Athens 1
Auckland 1
Badr 1
Bari 1
Bologna 1
Busto Arsizio 1
Campinas 1
Campo Bom 1
Casablanca 1
Chengdu 1
Cuiabá 1
Curitiba 1
Cáceres 1
Dezhou 1
Düsseldorf 1
Totale 2.796
Nome #
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model 128
Physical PEGylation to Prevent Insulin Fibrillation 128
Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment 122
408. Oncolytic Vaccines in Combination with PD-L1 Blockade for the Treatment of Melanoma 112
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma 98
220. Evaluation of the Efficacy of a New Oncolytic Vaccine Platform in Humanized Mice 95
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity 94
The evolution of adenoviral vectors through genetic and chemical surface modifications 94
Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity 92
Dexamethasone loaded liposomes by thin‐film hydration and microfluidic procedures: Formulation challenges 91
661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model 90
Thermosensitive "Smart" Surfaces for Biorecognition Based Cell Adhesion and Controlled Detachment 90
Heterologous and cross-species tropism of cancer-derived extracellular vesicles 89
Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. 89
622. Oncolytic Adenoviruses Loaded With Active Drugs as a Novel Drug Delivery System for Cancer Therapy 88
71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice 88
Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies 87
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma 83
The Anti-Proliferative Effect of L-Carnosine Correlates with a Decreased Expression of Hypoxia Inducible Factor 1 alpha in Human Colon Cancer Cells 82
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks 80
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model 74
From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review 72
Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation 72
Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform 71
Isoflavones in aglycone solution enhance ultraviolet B-induced DNA damage repair efficiency 70
Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma 69
null 66
Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells 66
PEG-polyaminoacid based micelles for controlled release of doxorubicin: Rational design, safety and efficacy study 65
Oncolytic adenovirus loaded with L-carnosine as a drug delivery system for cancer therapy 64
Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model 64
Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer 63
Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs 60
PCSK9 promotes arterial medial calcification 60
Transplantation of autologous extracellular vesicles for cancer-specific targeting 58
L-Carnosine and Human Colon Cancer 57
How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs 57
Screening of chemical linkers for development of pullulan bioconjugates for intravitreal ocular applications 57
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2 51
Application of array-CGH analysis in immune-virotherapy approach 37
Erratum: The anti-proliferative effect of L-carnosine correlates with a decreased expression of hypoxia inducible factor 1 alpha in human colon cancer cells (PLoS ONE (2014) 9, 5 (e96755) DOI: 10.1371/journal.pone.0096755) 37
Focused Design of Novel Cyclic Peptides Endowed with GABARAP-Inhibiting Activity 34
MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy 33
L-Carnosine inhibits KRAS-mediated HCT116 proliferation, by affecting ROS production and Hypoxia inducible factor (HIF-1) expression 30
I Vaccini 29
Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model 28
Extracellular vesicles powered cancer immunotherapy: Targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model 27
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus 25
Cancer vaccines: an update on recent achievements and prospects for cancer therapy 22
From Immunosuppression to Immunomodulation – Turning Cold Tumours into Hot 20
Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines 20
Oncologia 19
The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers 19
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects 18
Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model 15
Induction of an immune response by a nonreplicating adenoviruses-based formulation versus a commercial pseudo-SARS-CoV-2 vaccine 9
In vitro immune evaluation of adenoviral vector-based platform for infectious diseases 8
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model 8
Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency 6
Development of nanovehicles for co-delivery of colistin and ArnT inhibitors 5
Enhancing the activity of γ-hydroxy lactone derivatives as innovative peroxisome proliferator-activated receptor γ non-agonists inhibiting cyclin-dependent kinase 5-mediated phosphorylation 2
Totale 3.587
Categoria #
all - tutte 17.358
article - articoli 16.686
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 535
Totale 34.579


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020106 0 0 0 0 0 0 0 0 0 0 58 48
2020/2021718 48 77 48 27 70 16 69 82 82 70 86 43
2021/2022663 13 37 76 60 59 27 27 134 80 13 22 115
2022/2023335 73 1 4 23 70 46 1 38 46 3 15 15
2023/2024254 10 44 38 19 9 10 18 17 8 6 46 29
2024/2025754 9 44 41 51 130 55 71 90 89 49 125 0
Totale 3.587